We are live on ! Find out more
KLRS icon

Kalaris Therapeutics

71 hedge funds and large institutions have $33.9M invested in Kalaris Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

10,000% more call options, than puts

Call options by funds: $202K | Put options by funds: $2K

2.5% less ownership

Funds ownership: 43.22% → 40.72% (-2.5%)

7% less funds holding

Funds holding: 76 → 71 (-5)

14% less capital inflows, than outflows

Capital inflows: $6.28M | Capital outflows: $7.31M

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

36% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 25

Holders
71
Holders Change
-5
Holders Change %
-6.58%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
16
Reduced
25
Closed
19
Calls
$202​K
Puts
$2​K
Net Calls
+$200​K
Net Calls Change
-⁠$199​K

KLRS Hedge Fund Activity: Q2 2024 in Review

71 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2024, worth a combined $33.9M — down 7% from $36.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KLRS and 14 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 16 added.

The largest buyer was Octagon Capital Advisors, adding an estimated $4.3M. The largest seller was BlackRock, cutting an estimated $2.11M.

  • 71 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2024, down from 76 in Q1 2024.
  • Funds reported $33.9M of Kalaris Therapeutics stock for Q2 2024, down 7% quarter-over-quarter.
  • 14 funds opened new Kalaris Therapeutics positions in Q2 2024 and 19 closed out, a net change of -5 holders.
  • The largest Kalaris Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $4.3M added.
  • The largest Kalaris Therapeutics seller in Q2 2024 was BlackRock, an estimated $2.11M sold.

Based on aggregated 13F filings for Q2 2024.